1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL

 
• By Alaric DeArment

NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.

Acute myeloid leukemia a 3d-Render
Nkarta unveiled data for its CAR-NK therapies in AML and NHL • Source: Shutterstock

Preliminary Phase I data for Nkarta, Inc.’s allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies suggest the firm could have a strong showing in the CAR-NK race overall. The early data show strong response rates and depth of responses that could provide an indication of durability.

The company announced 25 April Phase I data for the NKG2D-targeting CAR-NK NKX101 in relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) and the CD19-targeting CAR-NK NKX019 in relapsed/refractory B-cell malignancies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 
• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

More from Anticancer